We are recruiting a bioinformatician post-doctoral fellow to work on metabolism and metastasis in lung cancer in #TRACERx & #PEACE - please do apply if interested (deadline 28 Apr'23): ucl.ac.uk/work-at-ucl/se…)

Labour Party Leader Keir Starmer and MP Wes Streeting MP visited this morning to discuss ways in which the UK can better diagnose, treat and prevent cancer. They were joined by Chief Executive of Cancer Research UK Michelle Mitchell and researchers Mariam Jamal-Hanjani and @SamraTurajlic

Published today Frontiers - Oncology: Phenotyping of CD45+ xenografts from the TRACERx lung cancer patient-derived xenograft (PDX) study. IgL/IgK restriction suggests primary tumours can contain multiple B cell clones with lymphoproliferative potential. doi.org/10.3389/fonc.2…

🚨 It’s a pleasure to announce I will be starting my own group later this year Early Cancer Institute, University of Cambridge CRUK Cambridge Centre! We’ll be leveraging non-invasive samples, e.g. ctDNA, to monitor somatic evolution. Please get in touch if you’d like to join me on this exciting new journey!

We're hiring! An exciting opportunity for a computational biologist to join the TRACERx team at the Francis Crick Institute. Apply by 31/08/23. ucl.ac.uk/work-at-ucl/re…

Last few days to apply. 👇. Deadline 31/08/23.

Thank you Siddhartha Mukherjee for taking the time out of your busy schedule to visit Swanton Lab Will Hill Clare Weeden Charles Swanton to talk about our work on air pollution and lung cancer The Crick

Absolutely stoked that 'Bug in the System: The past, present and future of cancer' has been picked up for Seriously - always a must-listen in my podcast app. Check out all 3 episodes here: bbc.co.uk/programmes/m00… #scicomm #cancer #cancerresearch #immunotherapy

Come start your group at the Crick! 💡 We're looking for creative early career researchers in cardiac and vascular biology, or clinician scientists in any field, to join our faculty community. #AcademicJobs | #ECRChat Apply by 5 October ⬇️ crick.ac.uk/careers-study/…

It has been great to collaborate with Hannah Greenwood, Tim Witney and team on their investigation of a new PET-based approach for imaging NRF2 activation in NSCLC. A tour de force across cell lines, GEMMs and CRUK Lung Centre PDX models!

Extremely grateful and excited to have support from Science and Innovation at Cancer Research UK to work on cancer initiation with Swanton Lab The Crick! Ever grateful to Jayant K. Rane Alex Frankell for the supervision and mentorship

Patient-derived xenograft (PDX) models allow cancer researchers to study tumour tissue from patients in mice. Our CRUK Lung Centre paper Nature Communications describes 48 new PDX models and highlights the importance of intratumor heterogeneity in the development of cancer models (1/9)

My Swanton Lab postdoc paper is now out Nature Communications. It was a huge privilege to work with the TRACERx team. Thanks to Ariana Huebner and Dave Pearce, as well as everyone else UCL Cancer Institute, The Crick and CRUK Manchester Institute who made this happen.

Patient-derived xenograft (PDX) models are widely used and valuable tools in #CancerResearch. But there are limitations to how well these models can represent the genetic complexity of patient tumours Rob Hynds Swanton Lab buff.ly/4aNLqDh Science and Innovation at Cancer Research UK The Crick UCL News

This study highlights the importance of considering primary tumor heterogeneity when using PDX models and emphasizes the benefit of comprehensive tumor sampling nature.com/articles/s4146…

New review out in Trends in Cancer from Chris Abbosh and Charles Swanton. Excellent summary of latest evidence & use case for ctDNA in NSCLC at diagnosis/landmark timepoints to help with staging and decisions around adjuvant treatment - worth reading #LCSM sciencedirect.com/science/articl…

Comment: Capturing heterogeneity in PDX models: representation matters nature.com/articles/s4146…

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Today our study of the association between replication timing alterations and mutation acquisition during cancer evolution has been published in Nature Communications nature.com/articles/s4146…

Is Osimertinib over? Not at all IMO. We just need to think more deeply about patient selection. I’ll point (again) to our recent paper looking at Genome Doubling and TP53 in EGFR positive NSCLC with @swantonlab nature.com/articles/s4146…